Aptadir Therapeutics emerged from stealth Tuesday with $1.6 million in pre-seed funding and a technology platform designed to reactivate genes that are suppressed in individuals with cancer and certain genetic conditions.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,